title: A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients.
abstract: Gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) may not be sensitive indicators of hepatocellular damage in patients taking anticonvulsant drugs as raised levels may only reflect enzyme induction. Aspartate aminotransferase (AST) is a specific, but relatively insensitive marker of liver damage and has a poor correlation with liver histology. Serum F protein is found in high concentration in the liver and levels are not influenced by enzyme induction. We measured serum F protein levels in patients taking carbamazepine (CBZ) and phenytoin (PHT) as monotherapy and in patients receiving multiple drugs. We compared the results with patients taking sodium valproate (VPA). Serum F protein levels were elevated in 6%, 22% and 13% of patients receiving CBZ, PHT and VPA, respectively. Raised GGT levels were reported for both the CBZ (26%) and PHT (78%) groups. Raised ALP levels were observed in 16%, 25% and 4% of the CBZ, PHT and VPA groups, respectively. Raised levels of serum F protein in the VPA group and the absence of any associated increases in either GGT or AST may further support the suggestion that serum F protein is an indicator of hepatocellular dysfunction associated with anticonvulsant therapy. However, further correlation with liver histology is required.
authors.affiliation: Department of Neurology, Cork Regional Hospital, Wilton, Ireland.
authors.forename: N
authors.initials: N
authors.lastname: Callaghan
authors.forename: T
authors.initials: T
authors.lastname: Majeed
authors.forename: A
authors.initials: A
authors.lastname: O'Connell
authors.forename: D B
authors.initials: DB
authors.lastname: Oliveira
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000201:enzymology; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy / Q000201:enzymology; D004827:Epilepsy / Q000188:drug therapy* / Q000201:enzymology; D004829:Epilepsy, Generalized / Q000188:drug therapy / Q000201:enzymology; D005260:Female; D006801:Humans; D007519:Isoantigens / Q000097:blood*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000927:Anticonvulsants; D007519:Isoantigens; C030497:liver specific F antigen; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase